ADIL (Adial Pharmaceuticals, Inc)
Insider Trading Activity
Every open-market purchase and sale reported by ADIL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-16 | Coastlands Capital LP | 10%+ Owner | Buy | — | — |
| 2026-07-13 | Coastlands Capital LP | 10%+ Owner | Buy | — | — |
| 2026-07-01 | Coastlands Capital LP | 10%+ Owner | Buy | — | — |
| 2026-06-16 | Wendy B. Young | Director | Buy | — | — |
| 2026-06-16 | Matt Davidson | Chief Development Officer | A | — | — |
| 2026-04-09 | J. Kermit Anderson | Director | A | — | — |
| 2026-04-09 | Vinay Shah | Chief Financial Officer | A | — | — |
| 2026-04-09 | Robertson H. Gilliland | Director | A | — | — |
| 2026-04-09 | Kevin Schuyler | Director | A | — | — |
| 2026-04-09 | Tony Goodman | Chief Operating Officer | A | — | — |
| 2026-04-09 | Cary J Claiborne | Chief Executive Officer | A | — | — |
| 2025-06-02 | J. Kermit Anderson | Director | A | — | — |
| 2025-06-02 | James W. Newman Jr. | Director | A | — | — |
| 2025-06-02 | Robertson H. Gilliland | Director | A | — | — |
| 2025-06-02 | Vinay Shah | Chief Financial Officer | A | — | — |
| 2025-06-02 | Cary J Claiborne | Chief Executive Officer | A | — | — |
| 2025-06-02 | Kevin Schuyler | Director | A | — | — |
| 2025-06-02 | Tony Goodman | Chief Operating Officer | A | — | — |
| 2024-12-05 | Cary J Claiborne | Chief Executive Officer | A | — | — |
| 2024-11-18 | Vinay Shah | Chief Financial Officer | A | — | — |
| 2024-03-27 | James W. Newman Jr. | Director | A | — | — |
| 2024-03-27 | Robertson H. Gilliland | Director | A | — | — |
| 2024-03-27 | Kevin Schuyler | Director | A | — | — |
| 2024-03-27 | J. Kermit Anderson | Director | A | — | — |
| 2024-03-27 | Cary J Claiborne | Chief Executive Officer | A | — | — |
| 2024-03-27 | Joseph Truluck | Chief Financial Officer | A | — | — |
| 2024-03-27 | Tony Goodman | Chief Operating Officer | A | — | — |
| 2023-10-03 | Kevin Schuyler | Director | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 387,075 | — |
| — | Chief Development Officer | 300,918 | — |
| — | Chief Executive Officer | 40,417 | — |
| — | Chief Operating Officer | 26,523 | — |
| — | Chief Financial Officer | 17,325 | — |
| — | Director | 9,217 | — |
| — | Director | 9,185 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ADIL quote page; the site-wide leaderboard is on the insider transactions hub.